<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699162</url>
  </required_header>
  <id_info>
    <org_study_id>DECS/JPO-CT-397-2020</org_study_id>
    <nct_id>NCT04699162</nct_id>
  </id_info>
  <brief_title>Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia</brief_title>
  <acronym>HGMHRAEI/ALL</acronym>
  <official_title>Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia. Experience of Two Centers in Mexico City</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Omar Ramos-Peñafiel, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to describe the survival and relapses of patients with diagnosis of&#xD;
      acute lymphoblastic leukemia at two tertiary level hospitals in the metropolitan area of the&#xD;
      valley of Mexico&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective, observational study in patients with diagnosis of acute lymphoblastic&#xD;
      leukemia, according to the criteria of the World Health Organization, from July, 2016, to&#xD;
      October, 2020. The patients were cared for in the hematology department of the Hospital&#xD;
      General de Mexico and in the hematology department of the Hospital Regional de Alta&#xD;
      Especialidad Ixtapaluca. Relapse was considered in those cases with more than 5% of blasts in&#xD;
      bone marrow and as relapse to the central nervous system with the presence of blasts in&#xD;
      cerebrospinal fluid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4-years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4-years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>4-years</time_frame>
    <description>Cases with more than 5 percent of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid</description>
  </primary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with first diagnosis of acute lymphoblastic leukemia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of acute lymphoblastic leukemia according to the criteria of&#xD;
             the World Health Organization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 15 years&#xD;
&#xD;
          -  Age over 60 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian O Ramos-Peñafiel, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de México Dr. Eduardo Liceaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad de Ixtapaluca</name>
      <address>
        <city>Ixtapaluca</city>
        <state>State Of Mexico</state>
        <zip>56530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Christian Omar Ramos-Peñafiel, MD, PhD</investigator_full_name>
    <investigator_title>Head of the hematology hospitalization area</investigator_title>
  </responsible_party>
  <keyword>Survival</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Relapse</keyword>
  <keyword>Retrospective study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

